The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus

• Published in: British journal of clinical pharmacology Vol. 76; no. 3; pp. 432 - 444
• Main Authors: Kasichayanula, Sreeneeranj, Liu, Xiaoni, Pe Benito, Melanie, Yao, Ming, Pfister, Marc, LaCreta, Frank P., Humphreys, William Griffith, Boulton, David W.
• Format: Journal Article
• Language: English
• Published: England Blackwell Science Inc 01.09.2013
• Subjects: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose - analysis; dapagliflozin; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - physiopathology; Diabetes Mellitus, Type 2 - urine; Dose-Response Relationship, Drug; Female; Glucosides - adverse effects; Glucosides - pharmacokinetics; Glucosides - pharmacology; Glucosides - therapeutic use; glucuronosyltransferase; Glycosuria - urine; Humans; Hypoglycemic Agents - adverse effects; Hypoglycemic Agents - pharmacokinetics; Hypoglycemic Agents - pharmacology; Hypoglycemic Agents - therapeutic use; Kidney - drug effects; Kidney - metabolism; Kidney - physiopathology; Kidney Function Tests; Liver - drug effects; Liver - metabolism; Liver - physiopathology; Male; Middle Aged; Pharmacokinetic Dynamic Relationships; renal insufficiency; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; type 2 diabetes mellitus; UGT1A9; Young Adult; sodium-glucose transporter 2; type 2 diabetes mellitus; glucuronosyltransferase; UGT1A9; dapagliflozin; renal insufficiency

Aim(s) This study assessed the effect of differences in renal function on the pharmacokinetics and pharmacodynamics of dapagliflozin, a renal sodium glucose co‐transporter‐2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus (T2DM). Methods A single 50 mg dose of dapagliflozin was used...